-
Mashup Score: 42
PURPOSE Prognostic Immunophenotyping in Myeloma Response (PRIMeR) is an ancillary study of minimal residual disease (MRD) assessment for multiple myeloma by next-generation multiparameter flow cytometry (MFC). Patients were enrolled on a three-arm randomized control trial (Blood and Marrow Transplants Clinical Trials Network 0702 Stem Cell Transplant for Myeloma in Combination of Novel Agents [STaMINA]; ClinicalTrials.gov identifier: NCT01109004). METHODS Four hundred and thirty-five patients consented to the MRD panel, which included 10 monoclonal antibodies measured via six-color MFC. MRD was measured at baseline/preautologous hematopoietic cell transplant (BL/preAutoHCT), premaintenance (PM), and 1 year (Y1) after AutoHCT with a sensitivity of 10–5 to 10–6. The primary objective was to assess MRD-negative (MRDneg) at 1 year after AutoHCT and progression-free survival and overall survival (PFS/OS). RESULTS Similar to the STaMINA results, at a median follow-up of 70 months, there was
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 32Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study - 9 day(s) ago
MicroabstractTreatment options for patients with relapsed/refractory multiple myeloma (RRMM) after relapse from allogeneic stem cell transplant (alloSCT) are needed. This study provides data around suitability of CAR-T therapy, specifically ciltacabtagene autoleucel, for heavily pretreated patients with RRMM and prior alloSCT. Patients in the CARTITUDE-1 study with prior alloSCT (n = 7) had similar efficacy and safety profiles to those without prior alloSCT.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 24Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis - 10 day(s) ago
FLC-MS can detect persistent light chains in a significant proportion of patients in a conventional hematologic CR.Patients with no detectable FLC by FLC-M
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 26Clonal Hematopoiesis of Indeterminate Potential in Patients with Immunoglobulin Light Chain AL Amyloidosis - 10 day(s) ago
Key Points. CHIP is more prevalent in AL amyloidosis patients than in the general populationCHIP presence was associated with the presence of t(11;14) and
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Large language models are getting bigger and better - 13 day(s) ago
Can they keep improving forever?
Source: www.economist.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1 - 13 day(s) ago
Key Points. Better clinical responses to teclistamab correlate with a more functional initial immune T-cell repertoire in the periphery and tumor siteMore
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 37CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma - 16 day(s) ago
Teclistamab is effective in real-world patients with R/RMM, including those with prior anti-BCMA therapy exposure, albeit with slightly poorer progression-
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma - 28 day(s) ago
Teclistamab is effective in real-world patients with R/RMM, including those with prior anti-BCMA therapy exposure, albeit with slightly poorer progression-
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
MRD negative status (10e-5 to -6) 1 year after AutoHCT and Len maintenance is associated with longer PFS and OS in MM. STaMINA trial #bmtsm #mmsm @mpasca @BMTCTN @BMTjunkie @Phari @JCO_ASCO https://t.co/d0ILmyxIQZ